Atrium Therapeutics Analyst Price Targets

Atrium Therapeutics Inc

RNANASDAQ

Trade with Public

$7.64

-0.03-0.39%

Ult. Agg.: Oct 19, 10:26 AM

$7.95

0.283.65%

Panoramica Notizie Previsioni utili EventiObiettivi di prezzoDati finanziari Sentiment Azionariato Confronta Opzioni Rapporto azionario

Atrium Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Atrium Therapeutics (RNA).

Price Target Range — 12 Quarters

Analyst Consensus — 18 Analysts

11Buy

7Hold

Consensus RatingBuy# Analysts18Avg. Consensus PT$60Upside to Avg. PT+686.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 14, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$25
Aug 6, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Initiate	Buy	$25
Jun 18, 2026	Cantor Fitzgerald	Kristen Kluska	Initiate	Overweight	$25
May 15, 2026	Leerink Partners	Joseph Schwartz	Initiate	Outperform	$25
May 1, 2026	HC Wainwright & Co.	Ananda Ghosh	Suspends	Neutral	—
Mar 11, 2026	Wells Fargo	Yanan Zhu	Initiate	Overweight	$25
Nov 11, 2025	Chardan Capital	Keay Nakae	Maintained	Neutral	$72
Oct 29, 2025	TD Cowen	Ritu Baral	Downgrade	Buy→Hold	$78→$74
Oct 28, 2025	Chardan Capital	Keay Nakae	Downgrade	Buy→Neutral	$75→$72
Oct 28, 2025	RBC Capital	Luca Issi	Downgrade	Outperform→Sector Perform	$61→$72
Oct 27, 2025	Citigroup	Geoff Meacham	Downgrade	Buy→Neutral	$75→$72
Oct 27, 2025	Leerink Partners	Joseph Schwartz	Downgrade	Outperform→Market Perform	$65→$72
Oct 27, 2025	Raymond James	Martin Auster	Downgrade	Strong Buy→Market Perform	—
Oct 27, 2025	Bernstein	William Pickering	Downgrade	Outperform→Market Perform	$52→$72
Oct 27, 2025	Needham	Joseph Stringer	Downgrade	Buy→Hold	$65
Oct 27, 2025	HC Wainwright & Co.	Ananda Ghosh	Downgrade	Buy→Neutral	$87→$72
Sep 22, 2025	Evercore ISI Group	Josh Schimmer	PT Cut	Outperform	$70→$65
Sep 17, 2025	Roth Capital	Boobalan Pachaiyappan	Initiate	Buy	$62
Sep 15, 2025	B of A Securities	Geoff Meacham	PT Raise	Buy	$56→$65
Sep 12, 2025	HC Wainwright & Co.	Ananda Ghosh	PT Raise	Buy	$68→$87

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Atrium Therapeutics, Maintains $25 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Atrium Therapeutics (NASDAQ:RNA) with a Buy and maintains $25 price target.

Benzinga Newsdesk

This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

Wall Street analysts change outlook on top names. Check analyst ratings page for all changes. See what analysts say about LYEL, IMRX, and RNA.

Avi Kapoor

PRO
HC Wainwright & Co. Initiates Coverage On Atrium Therapeutics with Buy Rating, Announces Price Target of $25

HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Atrium Therapeutics (NASDAQ:RNA) with a Buy rating and announces Price Target of $25.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Initiates Coverage On Atrium Therapeutics with Overweight Rating, Announces Price Target of $25

Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Atrium Therapeutics (NASDAQ:RNA) with a Overweight rating and announces Price Target of $25.

Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On Atrium Therapeutics with Outperform Rating, Announces Price Target of $25

Leerink Partners analyst Joseph Schwartz initiates coverage on Atrium Therapeutics (NASDAQ:RNA) with a Outperform rating and announces Price Target of $25.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Suspends Neutral Rating on Atrium Therapeutics

HC Wainwright & Co. suspends Neutral rating on Atrium Therapeutics (NASDAQ:RNA).

Benzinga Newsdesk

Atrium Therapeutics Inc

Atrium Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Atrium Therapeutics, Maintains $25 Price Target

This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

PRO
HC Wainwright & Co. Initiates Coverage On Atrium Therapeutics with Buy Rating, Announces Price Target of $25

PRO
Cantor Fitzgerald Initiates Coverage On Atrium Therapeutics with Overweight Rating, Announces Price Target of $25

PRO
Leerink Partners Initiates Coverage On Atrium Therapeutics with Outperform Rating, Announces Price Target of $25

PRO
HC Wainwright & Co. Suspends Neutral Rating on Atrium Therapeutics

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Atrium Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Atrium Therapeutics, Maintains $25 Price Target

This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

PRO
HC Wainwright & Co. Initiates Coverage On Atrium Therapeutics with Buy Rating, Announces Price Target of $25

PRO
Cantor Fitzgerald Initiates Coverage On Atrium Therapeutics with Overweight Rating, Announces Price Target of $25

PRO
Leerink Partners Initiates Coverage On Atrium Therapeutics with Outperform Rating, Announces Price Target of $25

PRO
HC Wainwright & Co. Suspends Neutral Rating on Atrium Therapeutics

People Also Watch

People Also Watch

Atrium Therapeutics Inc

Atrium Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Atrium Therapeutics, Maintains $25 Price Target

This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

PROHC Wainwright & Co. Initiates Coverage On Atrium Therapeutics with Buy Rating, Announces Price Target of $25

PROCantor Fitzgerald Initiates Coverage On Atrium Therapeutics with Overweight Rating, Announces Price Target of $25

PROLeerink Partners Initiates Coverage On Atrium Therapeutics with Outperform Rating, Announces Price Target of $25

PROHC Wainwright & Co. Suspends Neutral Rating on Atrium Therapeutics

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Atrium Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Atrium Therapeutics, Maintains $25 Price Target

This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

PROHC Wainwright & Co. Initiates Coverage On Atrium Therapeutics with Buy Rating, Announces Price Target of $25

PROCantor Fitzgerald Initiates Coverage On Atrium Therapeutics with Overweight Rating, Announces Price Target of $25

PROLeerink Partners Initiates Coverage On Atrium Therapeutics with Outperform Rating, Announces Price Target of $25

PROHC Wainwright & Co. Suspends Neutral Rating on Atrium Therapeutics

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Atrium Therapeutics, Maintains $25 Price Target

PRO
HC Wainwright & Co. Initiates Coverage On Atrium Therapeutics with Buy Rating, Announces Price Target of $25

PRO
Cantor Fitzgerald Initiates Coverage On Atrium Therapeutics with Overweight Rating, Announces Price Target of $25

PRO
Leerink Partners Initiates Coverage On Atrium Therapeutics with Outperform Rating, Announces Price Target of $25

PRO
HC Wainwright & Co. Suspends Neutral Rating on Atrium Therapeutics

PRO
HC Wainwright & Co. Reiterates Buy on Atrium Therapeutics, Maintains $25 Price Target

PRO
HC Wainwright & Co. Initiates Coverage On Atrium Therapeutics with Buy Rating, Announces Price Target of $25

PRO
Cantor Fitzgerald Initiates Coverage On Atrium Therapeutics with Overweight Rating, Announces Price Target of $25

PRO
Leerink Partners Initiates Coverage On Atrium Therapeutics with Outperform Rating, Announces Price Target of $25

PRO
HC Wainwright & Co. Suspends Neutral Rating on Atrium Therapeutics